CellCrine

CellCrine is a biotechnology company developing a proprietary BAP Chemically Defined Supplement (BAP-CDS) as a serum-free alternative to Fetal Bovine Serum (FBS) for cell culture applications. The company's technology eliminates the need for traditional growth factors by identifying and optimizing critical media components that induce potent cell signaling, and has been validated across more than 20 cell types including MSCs, CHO, HeLa, HEK293, stem cells, and cultivated meat cell lines. CellCrine targets the rapidly growing Chemically Defined Media market — projected to exceed $4 billion by 2026 — serving biopharmaceutical, cell therapy, regenerative medicine, and cultivated meat industries.